Research | Nyati Lab

The central mission of our laboratory is to develop more effective and durable cancer treatments by pioneering strategies in targeted protein degradation. Our research is organized into two primary, synergistic thrusts:

1. Optimizing Therapeutic Regimens through Mechanistic Insight

In this arm of our research, we focus on maximizing the efficacy of clinically approved drugs through novel, mechanism-based combinations. By leveraging a deep understanding of cellular signaling, we design logical therapeutic regimens where existing agents are repurposed to induce the selective degradation of key proteins involved in tumor survival and resistance. The goal is to achieve superior outcomes by strategically using the current therapeutic arsenal in new and more effective ways.

2. Development of Novel Oncoprotein Degraders

Our second major focus is the discovery and development of entirely new therapeutics designed specifically to degrade critical oncoproteins. This work involves creating first-in-class small molecules that target key cancer drivers, such as EGFR. Unlike traditional inhibitors that merely block protein function, our novel agents are engineered to trigger the complete elimination of the oncoprotein from the cancer cell. This approach is aimed at providing a definitive solution to acquired drug resistance and is currently advancing promising lead compounds toward clinical development.

Supporting both research arms is our collaborative work in biomarker discovery. By working with clinicians and industry partners, we aim to identify biomarkers that can predict patient response to these therapies. This will allow us to optimize treatment for individuals and ensure the right patients receive the right combination or novel therapeutic at the right time.